Advanced search
Publication Cover
Infectious Diseases Volume 51, 2019 - Issue 4
Submit an article Journal homepage
396
Views
9
CrossRef citations to date
0
Altmetric
Brief Report

Successful cure of daptomycin-non-susceptible, vancomycin-intermediate Staphylococcus aureus prosthetic aortic valve endocarditis directed by synergistic in vitro time-kill study

Zarchi E. SumonDepartment of Medicine, Infectious Diseases Division, University at Buffalo, Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY, USA; Correspondence[email protected]
,
Charles S. BerensonDepartment of Medicine, Infectious Diseases Division, University at Buffalo, Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY, USA; ;Department of Medicine, Infectious Diseases Division, Veterans Administration Western New York Healthcare System, Buffalo, NY, USA;
,
John A. SellickDepartment of Medicine, Infectious Diseases Division, University at Buffalo, Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY, USA; ;Department of Medicine, Infectious Diseases Division, Veterans Administration Western New York Healthcare System, Buffalo, NY, USA;
,
Zackery P. BulmanLaboratory for Antimicrobial Pharmacodynamics, University at Buffalo School of Pharmacy and Pharmaceutical Sciences, Buffalo, NY, USA;
,
Brian T. TsujiLaboratory for Antimicrobial Pharmacodynamics, University at Buffalo School of Pharmacy and Pharmaceutical Sciences, Buffalo, NY, USA;
&
Kari A. MergenhagenDepartment of Pharmacy, Veterans Administration Western New York Healthcare System, Buffalo, NY, USA
Pages 287-292 | Received 19 Apr 2018, Accepted 03 Oct 2018, Published online: 14 Feb 2019

References

  • Howden BP, Davies JK, Johnson PD, et al. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin Microbiol Rev. 2010;23:99–139.
  • Baxi SM, Clemenzi-Allen A, Gahbauer A, et al. Vancomycin MIC does not predict 90-day mortality, readmission, or recurrence in a prospective cohort of adults with Staphylococcus aureus bacteremia. Antimicrob Agents Chemother. 2016;60:5276–5284.
  • Hawkins C, Huang J, Jin N, et al. Persistent Staphylococcus aureus bacteremia: an analysis of risk factors and outcomes. Arch Intern Med. 2007;167:1861–1867.
  • McGuinness WA, Malachowa N, DeLeo FR. Vancomycin resistance in Staphylococcus aureus. Yale J Biol Med. 2017;90:269–281.
  • Charles PG, Ward PB, Johnson PD, et al. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin Infect Dis. 2004;38:448.
  • Bulitta JB, Ly NS, Yang JC, et al. Development and qualification of a pharmacodynamic model for the pronounced inoculum effect of ceftazidime against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2009;53:46–56.
  • Proctor RA, Kriegeskorte A, Kahl BC, et al. Staphylococcus aureus small colony variants (SCVs): a road map for the metabolic pathways involved in persistent infections. Front Cell Infect Microbiol. 2014;4:99.
  • Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association. Circulation. 2015;132:1435–1486.
  • Garaud JJ, Regnier B, Inglebert F, et al. Vancomycin pharmacokinetics in critically ill patients. J Antimicrob Chemother. 1984;14:53–57.
  • Cubicin (daptomycin for injection) [package insert]. Lexington, MA: Cubist Pharmaceuticals; 2003. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021572s038lbl.pdf11.
  • Teflaro (Ceftaroline fosamil) [package insert]. St Louis, MO: Forest Pharmaceuticals, Inc.; 2010. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/200327s001lbl.pdf12.
  • Mefoxin (Cefoxitin for infusion) [package insert]. Weston, FL: Apotex Corp.; 2015. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/050517s053lbl.pdf13.
  • Rifampin [package insert]. New York, NY: Pfizer Labs; 2011. https://products.sanofi.us/rifadin/Rifadin.pdf
  • Siber GR, Echeverria P, Smith AL, et al. Pharmacokinetics of gentamicin in children and adults. J Infect Dis. 1975;132:637–651.
  • Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis. 2011;52:285–292.
  • Jongsma K, Joson J, Heidari A. Ceftaroline in the treatment of concomitant methicillin-resistant and daptomycin-non-susceptible Staphylococcus aureus infective endocarditis and osteomyelitis: case report. J Antimicrob Chemother. 2013;68:1444–1445.
  • Sakoulas G, Moise PA, Casapao AM, et al. Antimicrobial salvage therapy for persistent staphylococcal bacteremia using daptomycin plus ceftaroline. Clin Ther. 2014;36:1317.
  • Dhand A, Bayer AS, Pogliano J, et al. Use of antistaphylococcal beta-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant Staphylococcus aureus: role of enhanced daptomycin binding. Clin Infect Dis. 2011;53:158–163.
  • Tattevin P, Basuino L, Bauer D, et al. Ceftobiprole is superior to vancomycin, daptomycin, and linezolid for treatment of experimental endocarditis in rabbits caused by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2010;54:610–613.
  • Polenakovik HM, Pleiman CM. Ceftaroline for meticillin-resistant Staphylococcus aureus bacteraemia: case series and review of the literature. Int J Antimicrob Agents. 2013;42:450–455.
  • Barber KE, Ireland CE, Bukavyn N, et al. Observation of seesaw effect with vancomycin, teicoplanin, daptomycin and ceftaroline in 150 unique MRSA strains. Infect Dis Ther. 2014;3:35–43.
  • Yang SJ, Xiong YQ, Boyle-Vavra S, et al. Daptomycin-oxacillin combinations in treatment of experimental endocarditis caused by daptomycin-nonsusceptible strains of methicillin-resistant Staphylococcus aureus with evolving oxacillin susceptibility (the seesaw effect). Antimicrob Agents Chemother. 2010;54:3161–3169.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.